SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-320325
Filing Date
2021-11-04
Accepted
2021-11-04 16:59:10
Documents
13
Period of Report
2021-11-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d212515d8k.htm   iXBRL 8-K 30089
2 EX-1.1 d212515dex11.htm EX-1.1 200867
  Complete submission text file 0001193125-21-320325.txt   408433

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fate-20211104.xsd EX-101.SCH 2916
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20211104_lab.xml EX-101.LAB 17374
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20211104_pre.xml EX-101.PRE 10969
6 EXTRACTED XBRL INSTANCE DOCUMENT d212515d8k_htm.xml XML 3276
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 211380927
SIC: 2836 Biological Products, (No Diagnostic Substances)